| Code | CSB-RA013510MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Narsoplimab, targeting mannan-binding lectin serine protease 2 (MASP2), a critical effector enzyme in the lectin pathway of complement activation. MASP2 functions as the primary activator of the complement cascade through this pathway, cleaving C4 and C2 to generate the C3 convertase. The lectin pathway plays a significant role in innate immunity and inflammatory responses, with aberrant MASP2 activity implicated in various complement-mediated disorders including thrombotic microangiopathies, hematopoietic stem cell transplant-associated complications, IgA nephropathy, and antibody-mediated transplant rejection.
Narsoplimab represents the first-in-class MASP2 inhibitor designed to selectively block lectin pathway activation while preserving other complement pathways. This biosimilar antibody provides researchers with a valuable tool for investigating lectin pathway mechanisms, studying complement-mediated pathological processes, and exploring therapeutic interventions in complement-related diseases. It serves as an essential reagent for complement biology research and preclinical studies examining MASP2 inhibition strategies.
There are currently no reviews for this product.